CBIO compared with DMRA: revenue, margins and what each company keeps, and the suppliers and customers both name

CBIOCrescent Biopharma, Inc.

Mkt capRevenueRevenue

DMRADamora Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

CBIOCrescent Biopharma, Inc.

DMRADamora Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only CBIO 5

CRLCharles River Laboratoriessupplier

—Paragon Therapeuticsunlistedsupplier

—WuXi Biologics (Hong Kong)unlistedsupplier

—WuXi Biologics Irelandunlistedsupplier

1 more · CBIO chain ›

Shared 0

No shared counterparties.

Only DMRA 3

—Paragonunlistedsupplier

—Pre-Acquisition Damoraunlistedsupplier

—Bridge Medicinesunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

CBIOCrescent Biopharma, Inc.

13.55▲+3.73%· post 13.75

Mkt cap$485.1MRevenue$1MQ1 FY26

DMRADamora Therapeutics, Inc.

22.84▲+3.45%· post 22.84

ClosedNov 4 '26

Mkt cap$1.4BRevenue—

Compare

ClosedNov 4 '26

CBIOCrescent Biopharma, Inc.

DMRADamora Therapeutics, Inc.

13.55▲+3.73%post 13.75

Price

22.84▲+3.45%post 22.84

$485.1M

Mkt cap

$1.4B

Q1 FY26$1M

Revenue

—

CBIO13.55▲+3.73%vsDMRA22.84▲+3.45%ClosedNov 4 '26